Efficacy of adipose-derived stem cells and stromal vascular fraction for pain relief in Kellgren-Lawrence grade II-III knee osteoarthritis: A systematic review (2019–2024)

ADMSC and SVF stem cell therapies represent promising non-surgical options for managing knee osteoarthritis (KOA) in patients over 40. ADMSC demonstrates higher efficacy in sustaining long-term pain relief and joint health, with significant potential for cartilage regeneration. The chondrogenic properties of ADMSCs make them particularly beneficial for patients younger than 62 years old. Conversely, SVF, with its heterogeneous cell composition, provides rapid paracrine effects, offering early symptom relief and broader applicability for older or obese patients, including those with a Body Mass Index (BMI) over 30.